시장보고서

상품코드

1800914

낭포성 섬유증 치료 시장 보고서 : 약제 클래스별, 약제 분자 유형별, 투여 경로별, 최종사용자별, 지역별(2025-2033년)

Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2025-2033

발행일: 2025년 08월 | 리서치사:

IMARC | 페이지 정보: 영문 118 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 낭포성 섬유증 치료 시장 규모는 2024년 78억 달러에 달했습니다. IMARC Group은 2033년까지 시장 규모가 155억 달러에 달하고, 2025-2033년 7.55%의 연평균 성장률(CAGR)을 보일 것으로 예측했습니다. 낭포성 섬유증의 유병률 증가, 유전적 요인에 기반한 개인별 맞춤 치료 접근법에 대한 선호도 증가, 유전자 치료의 최근 발전의 광범위한 활용은 시장 성장을 가속하는 주요 요인 중 일부입니다.

낭포성 섬유증 치료는 호흡기 및 소화기 계통에 영향을 미치는 유전성 질환의 증상 관리를 가능하게 합니다. CFTR 조절제, 유전자 치료제를 포함한 다양한 약물이 포함되어 있으며, 맞춤형 치료 옵션을 제공합니다. CFTR 단백질의 기능을 강화하여 CF의 원인이 되는 근본적인 유전자 이상을 개선합니다. 증상을 개선하고 질병의 진행을 지연시켜 삶의 질 향상에 기여합니다. 폐 기능을 강화하여 CF 환자의 호흡을 편안하게 하고 호흡기 증상을 완화할 수 있습니다.

유전적 요인에 기반한 개인별 맞춤 치료에 대한 선호도가 높아지면서 시장 성장세가 강화되고 있습니다. 이와는 별도로 각국 정부 당국이 CF 연구 및 치료제 개발을 위한 정책 및 자금을 도입하고 있어 시장 전망을 밝게 하고 있습니다. 또한, 희귀질환 치료제 개발에 대한 규제 혜택이 지속적으로 증가하면서 제약사들의 CF 치료제 투자를 촉진하고 있습니다. 또한, 제약사, 연구 개발 기관, 의료 서비스 제공업체 간의 협력이 강화되면서 새로운 치료법 개발이 가속화되고 있습니다. 또한, 웨어러블 기기, 원격의료 등의 기술 보급으로 환자 모니터링 및 치료 제공이 강화되고 있습니다.

낭포성 섬유증 치료 시장 동향 및 촉진요인:

CFTR 모듈레이터의 발전

CFTR 조절제의 개발과 지속적인 개선은 시장 성장에 기여하는 주요 요인 중 하나입니다. 이 약품들은 CF 환자에서 두꺼운 점액 생성 및 그에 따른 건강 합병증을 유발하는 결함 있는 CFTR 단백질을 직접적으로 표적으로 삼는다. 이와는 별도로, 제약사들은 더 높은 효능과 광범위한 적용성을 제공하는 차세대 CFTR 모듈레이터를 도입하기 위한 연구 개발 활동에 지속적으로 투자하고 있습니다. 이러한 발전은 보다 종합적인 솔루션을 제공하고 환자의 전반적인 건강을 개선할 수 있습니다. 또한, 특정 CF 환자군의 점액 청소율 개선, 호흡기 증상 완화, 폐 기능 개선에도 도움을 줄 수 있습니다.

유전자 기반 치료제 개발

유전자 기반 치료제 개발도 시장 개척을 촉진하는 큰 요인입니다. 이 혁신적인 치료법은 CFTR 유전자의 기능 장애 사본을 감염된 세포에 도입하여 CF의 근본 원인을 해결하고 CF의 치유와 장기적인 관리를 용이하게 합니다. 또한, 카프트리오(Kaftrio)와 트리카프타(Trikafta)와 같은 유전자 기반 치료제가 CF 증상을 치료하기 위해 승인되는 등 최근 유전자 치료의 발전이 증가하고 있는 것도 시장 전망을 밝게 하고 있습니다. 이와는 별도로 유전자 기반 치료법의 진화가 시장 성장을 강화하고 있습니다. 이러한 치료법은 보다 효과적이고 표적화된 치료를 제공하고, 치료 옵션을 넓히며, 잠재적 치료법 연구를 촉진하는 데 도움이 되고 있습니다.

유병률 증가와 조기 진단

여러 요인, 특히 밀레니얼 세대의 CF 유병률 증가로 인해 치료제에 대한 수요가 증가하고 있습니다. 이에 따라 진단 능력의 향상으로 시장 전망을 밝게 하고 있습니다. 또한, 의료 시스템은 신생아 검진 프로그램과 유전자 검사를 통해 CF 환자를 식별하는 데 익숙해지고 있습니다. 이와는 별개로 조기 진단을 통해 젊은 나이에 치료를 시작할 수 있어 질병의 진행에 큰 영향을 미치고 장기적인 결과를 개선할 수 있습니다. 또한, 유전자 검사와 신생아 선별검사 프로그램의 발전으로 영유아의 CF 진단이 더욱 신속하고 확실하게 이루어지고 있습니다.

The global cystic fibrosis therapeutics market size reached USD 7.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.5 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033. The rising prevalence of cystic fibrosis, increasing preferences of individuals for personalized treatment approaches based on genetic factors, and the widespread utilization of recent advancements in gene therapy are some of the major factors propelling the market growth.

Cystic fibrosis therapeutics enables management of the symptoms of a genetic disease affecting the respiratory and digestive systems. It encompasses a range of drugs, including CFTR modulators and gene therapy, offering tailored treatment options. It helps correct the underlying genetic defect responsible for CF by enhancing the function of the CFTR protein. It contributes to a better quality of life by managing symptoms and slowing disease progression. It can enhance lung function, helping individuals with CF breathe more easily and reducing respiratory symptoms.

Rising preferences of individuals for personalized treatment approaches based on genetic factors is strengthening the growth of the market. Apart from this, governing authorities of various countries are introducing policies and funding for CF research and treatment development, which is offering a favorable market outlook. Additionally, a continuous rise in regulatory incentives for orphan drug development is encouraging pharmaceutical companies to invest in CF therapeutics. Moreover, the rising collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development of new therapies. Furthermore, the widespread use of technology, such as wearable devices and telemedicine, is enhancing patient monitoring and treatment delivery.

Cystic Fibrosis Therapeutics Market Trends/Drivers:

Advancements in CFTR modulators

The development and continued improvement of CFTR modulator drugs represent one of the primary factors contributing to the market growth. These medications directly target the defective CFTR protein, which is responsible for the thick mucus production and subsequent health complications in individuals with CF. Apart from this, pharmaceutical companies are continuously investing in research and development (R&D) activities to introduce new generations of CFTR modulators that offer greater effectiveness and broader applicability. These advancements provide more comprehensive solutions and improve the overall well-being of individuals. They also support improved mucus clearance, reduced respiratory symptoms, and enhanced lung function in specific CF patient populations.

Development of gene-based therapies

The development of gene-based therapies is another major factor facilitating the market growth. These innovative treatments help address the root cause of CF by introducing functional copies of the defective CFTR gene into affected cells and facilitating a cure or long-term management of CF. Additionally, the rising utilization of recent advancements in gene therapy, such as the approval of gene-based treatments like Kaftrio and Trikafta for treating CF symptoms is offering a favorable market outlook. Apart from this, the evolution of gene-based therapies is strengthening the growth of the market. These therapies aid in providing more effective and targeted treatments, expanding treatment options, and fostering research into potential curative approaches.

Increasing prevalence and early diagnosis

The rising prevalence of CF, especially among the millennial population due to several factors, is driving the demand for therapeutics. Along with this, improved diagnostic capabilities are creating a positive market outlook. Additionally, healthcare systems are becoming more adept at identifying CF cases through newborn screening programs and genetic testing. Apart from this, early diagnosis allows for the initiation of treatment at a younger age, which can significantly impact disease progression and improve long-term outcomes. Furthermore, ongoing advancements in genetic testing and newborn screening programs are allowing for quicker and more reliable diagnosis of CF in infants and young children.

Cystic Fibrosis Therapeutics Industry Segmentation:

Breakup by Drug Class:

Pancreatic Enzyme Supplements
Mucolytics
Bronchodilators
CFTR Modulators
Antibiotics
Others

CFTR modulators hold the largest market share

Breakup by Drug Molecule Type:

Small Molecule Drugs
Biologics

Small molecule drugs account for the majority of the market share

Breakup by Route of Administration:

Oral Drugs
Inhaled Drugs

Oral drugs dominate the market

Breakup by End-User:

Hospitals
Clinics
Others

Hospitals dominate the market

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Europe leads the market, accounting for the largest cystic fibrosis therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share since the region has a well-developed healthcare infrastructure with widespread access to medical facilities and specialized CF centers. Additionally, Europe has a relatively high prevalence of CF. This increased prevalence drives research and development (R&D) efforts as well as market demand for CF therapeutics. Apart from this, Europe is home to some of the largest pharmaceutical companies in the world. These companies invest heavily in CF therapeutics, leading to the development of innovative treatments. Furthermore, the European Medicines Agency (EMA) provides a clear regulatory pathway for the approval of CF drugs. Moreover, many European governments allocate substantial funding to support CF research and treatment. This funding accelerates the development of new therapies and promotes market growth.

Competitive Landscape:

Companies are investing heavily in research and development (R&D) activities to discover new treatments and medications that target the underlying causes of cystic fibrosis. Additionally, they are working on therapies tailored to specific genetic mutations associated with cystic fibrosis. This ensures a more effective and targeted approach to treatment. Apart from this, many companies are forming partnerships with academic institutions, research organizations, and other pharma companies to accelerate drug development and bring new therapies to market more quickly. Furthermore, they are continuously conducting and investing in phase I, II, and III clinical trials to test the efficacy and safety of new cystic fibrosis therapies.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.
Alaxia
Alcresta Therapeutics Inc.
Allergan
AstraZeneca
F. Hoffmann-La Roche Ltd.
Gilead Sciences Inc.
Merck & Co. Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc.

Key Questions Answered in This Report:

How has the global cystic fibrosis therapeutics market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global cystic fibrosis therapeutics market?
What is the impact of each driver, restraint, and opportunity on the global cystic fibrosis therapeutics market?
What are the key regional markets?
Which countries represent the most attractive cystic fibrosis therapeutics market?
What is the breakup of the market based on the drug class?
Which is the most attractive drug class in the cystic fibrosis therapeutics market?
What is the breakup of the market based on the drug molecule type?
Which is the most attractive drug molecule type in the cystic fibrosis therapeutics market?
What is the breakup of the market based on the route of administration?
Which is the most attractive route of administration in the cystic fibrosis therapeutics market?
What is the breakup of the market based on the end-user?
Which is the most attractive end-user in the cystic fibrosis therapeutics market?
What is the competitive structure of the global cystic fibrosis therapeutics market?
Who are the key players/companies in the global cystic fibrosis therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class

6.1 Pancreatic Enzyme Supplements
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Mucolytics
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Bronchodilators
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 CFTR Modulators
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Antibiotics
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

7.1 Small Molecule Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Biologics
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Oral Drugs
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Inhaled Drugs
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by End-User

9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Clinics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Abbvie Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Alaxia
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
- 15.3.3 Alcresta Therapeutics Inc.
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
- 15.3.4 Allergan
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 AstraZeneca
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 F. Hoffmann-La Roche Ltd
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
- 15.3.7 Gilead Sciences Inc.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Merck & Co., Inc.
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Novartis AG
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Teva Pharmaceutical Industries Ltd.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Vertex Pharmaceuticals Inc.
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis

낭포성 섬유증 치료 시장 보고서 : 약제 클래스별, 약제 분자 유형별, 투여 경로별, 최종사용자별, 지역별(2025-2033년)

Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2025-2033

낭포성 섬유증 치료 시장 동향 및 촉진요인:

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 서론

제5장 세계의 낭포성 섬유증 치료 시장

제6장 시장 분석 : 약제 클래스별

제7장 시장 분석 : 약물 분자 유형별

제8장 시장 분석 : 투여 경로별

제9장 시장 분석 : 최종사용자별

제10장 시장 분석 : 지역별

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter의 Five Forces 분석

제14장 가격 분석

제15장 경쟁 구도